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Chronic daily headache (CDH) refers to a group of
headache disorders that occur on at least 15 days per
month.1 It is frequently associated with the overuse of
pain medications and comorbid psychiatric conditions
such as anxiety and depression. Although CDH is not
life-threatening, it often causes considerable disability
and compromises the quality of life of those who suffer
from it. Therefore, the management of CDH is a
challenge for many clinicians.2
One of the most common subtypes of CDH is trans-
formed migraine (TM), also known as chronic migraine
(CM). Patients with TM usually have a history of epi-
sodic migraine which over the years gradually increases
in frequency to become CDH, but decrease in the
severity of migraine features.1 In TM, acute migraine
attacks are treated as migraine, but their prevention is
difficult.3 Conventional preventive treatments for TM
include the use of β-blockers, tricyclic antidepressants,
and anticonvulsants, but the results are less than satis-
factory.2 The systemic side effects of these medications
also limit their usefulness as prophylactic treatments.
To date, there are no randomized controlled trials of
preventive therapy aimed exclusively at TM.
In the past 10 years, botulinum toxin A (BoNT-A)
has emerged as a treatment for headaches, and it has
been found to be safe and well tolerated in general.4
Several open-label studies of BoNT-A treatment with
small numbers of patients have reported that it is benefi-
cial for CDH. In this issue, Liu et al5 retrospectively
analyzed the efficacy of BoNT-A in 30 consecutive
patients with TM. After a single injection of a low
dose of BoNT-A, 27 of the 30 patients reported at least
a 50% reduction in either the number of headache days
or in headache intensity. The authors concluded that
BoNT-A is a promising prophylactic treatment for
TM for patients in Taiwan.
On the other hand, 3 randomized, double-blind,
placebo-controlled studies of BoNT-A for the treat-
ment of CDH found negative results for their pri-
mary efficacy endpoint measured by the change from
baseline in the frequency of headache-free days.6–8 All
3 studies included patients with TM, but did not sep-
arately examine the efficacy of BoNT-A for those
patients. Subgroup analysis of the study by Mathew 
et al8 showed a significant reduction in the frequency
of headaches in CDH patients who were not using
other prophylactic medications.9
The mixed findings of the efficacy of BoNT-A in
CDH prophylaxis shows the need to identify those
patients who may benefit from BoNT-A. The report
by Liu et al5 indicates that it is likely that patients 
with TM may represent a subgroup of migrainers
who respond better to BoNT-A, but further studies
are needed. This issue is important in clinical practice
because BoNT-A is costly and at the present time its
use for headache prevention is not reimbursed by the
National Health Insurance of Taiwan.
In the past decade, the epidemiology of headache
and its subtypes has been extensively studied. Wang10
reported that the prevalence rates of CDH in Taiwan
(3.2–3.9%) were similar to those in Western countries
(3.0–4.7%). However, the inclination to seek medical
attention and the response to BoNT-A treatment
might be different between the 2 groups. Perhaps it is
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time to conduct a well-designed, large, multicenter,
randomized, double-blind, placebo-controlled study
of BoNT-A for the prevention of CDH in Taiwan.
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